Kathryn Effendi

Kathryn Effendi

Auto-generated profile, based on publicly available information

Kathryn Effendi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YKYutaka Kurebayashi
Yutaka Kurebayashi
KSKatsutoshi Sugimoto
Katsutoshi Sugimoto
HTHanako Tsujikawa
Hanako Tsujikawa
KMKosuke Matsuda
Kosuke Matsuda
RNRui Nomura
Rui Nomura
MSMichiie Sakamoto
Michiie Sakamoto
Purpose: Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear. Experimental Design: We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed. Results: We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions. Conclusions: We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.

23 May 2024 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Open access
Kathryn EffendiKathryn Effendi
Kathryn Effendi
NRNur Rahadiani
Nur Rahadiani
MSMarini Stephanie
Marini Stephanie
YKYutaka Kurebayashi
Yutaka Kurebayashi
HTHanako Tsujikawa
Hanako Tsujikawa
MSMichiie Sakamoto
Michiie Sakamoto
Standardized pathological evaluation based on immunohistochemical (IHC) analysis could improve hepatocellular carcinoma (HCC) diagnoses worldwide. We evaluated differences in clinicopathological subgroups in HCCs from two academic institutions in Tokyo-Japan, and Jakarta-Indonesia. Clinicopathological parameters and molecular expression patterns were evaluated in 35 HCCs from Indonesia and 41 HCCs from Japan. IHC analysis of biliary/stem cell (B/S) markers (cytokeratin 19, sal-like protein 4, epithelial cell adhesion molecule) and Wnt/β-catenin (W/B) signaling-related molecules (β-catenin, glutamine synthetase) could determine the IHC-based subgroups. For immuno-subtypes categorization, CD3/CD79α double immunohistochemistry was done to evaluate the infiltration of T and B cells. CD34 staining allowed identification of vessels that encapsulated tumor clusters (VETC). Indonesian HCC patients were mostly <60 years old (66%) with a hepatitis B virus (HBV) background (82%), in contrast to Japanese HCC patients (8% and 19%, respectively, both P < 0.001). In comparison with Japanese, Indonesian cases more frequently had >5 cm tumor size (74% vs 23%, P = 0.001), poor differentiation (40% vs 24%), portal vein invasion (80% vs 61%), and α-fetoprotein levels >500 ng/ml (45% vs 13%, P = 0.005). No significant differences were found in the proportions of B/S, W/B, and -/- subgroups from both countries. No immune-high tumors were observed among Indonesian cases, and immune-low tumors (66%) were more common than in Japanese cases (54%). VETC-positive tumors in Indonesia were significantly more common (29%), and most were in the HBV (90%) and -/- subgroups (90%), whereas Japanese VETC cases (10%, P = 0.030) were nonviral (100%) and W/B subgroups (75%). IHC-based analysis more precisely reflected the clinicopathological differences of HCCs in Japan and Indonesia. These findings provide new insights into standardization attempts and HCC heterogeneity among countries.

13 June 2022 in Universa Medicina
Verified
Journal Article
Open access
PDF file
Kathryn EffendiKathryn Effendi
Kathryn Effendi
WKWit Thun Kwa
Wit Thun Kwa
AUAkihisa Ueno
Akihisa Ueno
MSMichiie Sakamoto
Michiie Sakamoto
Universa Medicina is a four-monthly medical journal that publishes new research findings on a wide variety of topics of importance to biomedical science and clinical practice

19 May 2023 in Universa Medicina
Verified
Journal Article
Open access
PDF file
Kathryn EffendiKathryn Effendi
Kathryn Effendi
Universa Medicina is a four-monthly medical journal that publishes new research findings on a wide variety of topics of importance to biomedical science and clinical practice

16 December 2024
Verified
Other
Open access
YKYutaka Kurebayashi
Yutaka Kurebayashi
KSKatsutoshi Sugimoto
Katsutoshi Sugimoto
HTHanako Tsujikawa
Hanako Tsujikawa
KMKosuke Matsuda
Kosuke Matsuda
RNRui Nomura
Rui Nomura
MSMichiie Sakamoto
Michiie Sakamoto
Figure S3. CXCL13, PD1, and CXCR5 expression in Tfh cells

16 December 2024
Verified
Other
Open access
YKYutaka Kurebayashi
Yutaka Kurebayashi
KSKatsutoshi Sugimoto
Katsutoshi Sugimoto
HTHanako Tsujikawa
Hanako Tsujikawa
KMKosuke Matsuda
Kosuke Matsuda
RNRui Nomura
Rui Nomura
MSMichiie Sakamoto
Michiie Sakamoto
Table S8. Details of multiplex immunohistochemistry panels and definition of each CD8 and CD4 T cell population